Drug intelligence / Profile preview

Papilovax

Development stage: Unknown
Lead developer: Xiamen Innovax Biotech
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**Papilovax** is a marketed bivalent prophylactic human papillomavirus vaccine from Incepta Vaccine for prevention of HPV-16- and HPV-18-associated cervical disease in females aged 9–45 years. Each 0.5 mL dose contains recombinant HPV type 16 L1 protein and HPV type 18 L1 protein, produced in *Escherichia coli*, self-assembled into virus-like particles and adsorbed to aluminum hydroxide. It is supplied as a prefilled-syringe suspension for intramuscular administration and is indicated to prevent cervical cancer, cervical intraepithelial neoplasia, adenocarcinoma in situ, and persistent HPV-16/18 infection. ([inceptavaccine.com](https://inceptavaccine.com/product-details.php?pid=papilovax))

Brand names: Papilovax
Other names: Human Papillomavirus Vaccine (rDNA) BP

Beyond the preview

Go deeper on Papilovax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Papilovax.

Explore the full profile